Abstract
This paper summarizes the peculiarities of HPMA copolymerbound doxorubicin as an anticancer drug. It was found that polymer-bound doxorubicin demonstrated higher anticancer activity compared with free doxorubicin. This phenomenon was explained by the following mechanisms of its anticancer action: preferential accumulation in tumors, internalization in membrane-limited organelles, ability to overcome existing multidrug resistance and not to induce it de novo, high intracellular toxicity and inhibition of detoxification enzymes, cell death induction by the activation of specific signaling pathways, and triggering of caspase activation cascades.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
